Real-world comparative study in Sweden shows that FreeStyle Libre system use is associated with lower HbA1c levels for people with Type 2 diabetes using insulin therapy.

Abbott has today announced an update to its FreeStyle LibreLink app, which will allow people who use the FreeStyle Libre 2 system to get real-time minute-by-minute glucose readings automatically displayed on the app.

Abbott today announced that its FreeStyle Libre® 3 sensor – the first continuous glucose monitor (CGM) with readings every minute – is now authorised to work with Ypsomed’s mylife™ YpsoPump and CamDiab's CamAPS FX mobile app in a major step forward for Type 1 diabetes management in the UK.

A new survey from global healthcare company, Abbott, has found that over a third (37%) of Brits either don’t know or are misinformed as to what illnesses antibiotics can effectively treat. 

With diabetes prevalence expected to reach almost 5.5 million across the UK by 2030ii, new results from a first-of-its-kind survey by Abbott has identified a clear disconnect between the perceptions of the British public and those living with diabetes when it comes to stigma surrounding the condition.

Abbott’s FreeStyle Libre® systems and Novo Nordisk’s smart connected insulin pens now work together to help people manage their diabetes in a simpler, more integrated way.

Abbott’s NeuroSphere™ Virtual Clinic, The UK’s first   remote neuromodulation patient-care technology, is now available in six specialist centres across the UK.

Abbott today announced new data from the Real World Evidence of FreeStyle Libre (RELIEF) study showing the use of the FreeStyle Libre continuous glucose monitoring system (CGM) significantly reduced the rate of hospitalisations due to acute diabetes events (ADEs) for people living with type 2 diabetes on once-daily (basal) insulin therapy.